Highlights Janux Therapeutics, Inc.

Equities

JANX

US47103J1051

Market Closed - Nasdaq Other stock markets 21:00:00 20/06/2024 BST			5-day change	1st Jan Change
40.3 ^USD	-0.25%		-4.89%	+275.58%

06-06	Janux Therapeutics Insider Sold Shares Worth $45,043,975, According to a Recent SEC Filing	MT
06-06	Janux Therapeutics Insider Sold Shares Worth $82,125,000, According to a Recent SEC Filing	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	04-10	MT
Sector Update: Health Care	04-10	MT
Janux Therapeutics Said to be Considering Sale	04-10	MT
Janux Therapeutics Considering Options, Including Sale, Bloomberg Reports	04-10	MT
Janux Therapeutics Reportedly Weighs Possible Sale	04-09	CI
Janux Therapeutics Q4 Net Loss Narrows, Revenue Decreases	03-08	MT
Janux Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-08	CI
Janux Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-08	CI
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday as Investors Await Key Data for Rate-Cut Hints	02-27	MT
Janux Therapeutics, Inc. Announces Positive Updated Clinical Data for Both of its Clinical Programs	02-26	CI
Janux Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Janux Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/08/23	CI
Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1A Dose Escalation for Psma-Tractr Janx007 and an Update on Pipeline Programs	17/07/23	CI
Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/05/23	CI
Janux Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	10/03/23	CI
Janux Therapeutics' Q4 Loss Widens, Revenue Rises	10/03/23	MT
Janux Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	10/03/23	CI
Janux Therapeutics Submits Investigational New Drug Application to FDA for Drug to Treat Solid Tumors	27/12/22	MT
Janux Therapeutics, Inc. Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors	27/12/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Janux Therapeutics, Inc.

Equities

JANX

US47103J1051

Highlights

Filters